Protease inhibitor monotherapy: What is its role?

Current HIV/AIDS Reports

Volumn 9, Issue 2, 2012, Pages 179-185

  Estébanez, Miriam ^a   Arribas, Jose R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapies; Lipoatrophy. Bone mineral density; Monotherapy; Protease inhibitor

Indexed keywords

ABACAVIR; C REACTIVE PROTEIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; FOSAMPRENAVIR; INTERLEUKIN 6; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR; VIRUS RNA; VITAMIN D; ZIDOVUDINE; CARBAMIC ACID DERIVATIVE; LOPINAVIR RITONAVIR DRUG COMBINATION; LOPINAVIR-RITONAVIR DRUG COMBINATION; ORGANOPHOSPHATE; SULFONAMIDE;

ARTICLE; BODY FAT DISTRIBUTION; BONE DENSITY; BONE MARROW TOXICITY; BONE METABOLISM; DRUG PENETRATION; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MONOTHERAPY; MORTALITY; NEUROLOGIC DISEASE; RISK; VIRUS LOAD; VIRUS REPLICATION; ADIPOSE TISSUE; ANTIVIRAL RESISTANCE; DRUG COMBINATION; DRUG EFFECT; REVIEW; VIROLOGY;

ADIPOSE TISSUE; BONE DENSITY; CARBAMATES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; LOPINAVIR; PHOSPHORIC ACID ESTERS; PROTEASE INHIBITORS; RITONAVIR; SULFONAMIDES;

EID: 84864024380     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0112-1     Document Type: Article

References (47)

1. Reiss P, Battegay M, Clumeck N, et al. European AIDS Clinical Society Guidelines. Version 6.0. Octuber 2011. http://www.europeanaidsclinicalsociety. org/index.php?option=com-content&view=article&id=59:eacs- guidelines&catid=37:guidelines&Itemid=41 (last accessed 10/January/2012).
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166.
3. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel. JAMA. 2010;304:321-33.
4. Bierman WF, van Agtmael MA, Nijhuis M, et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009;23:279-91.
5. Pérez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis. 2011;24:7-11.
6. Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6:e22003.
7. Perez-Valero I, Bayon C, Cambron I, et al. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother. 2011;66:1954-62.
8. Arribas J, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA <50 copies/mL at baseline. [Abstract MOPE216]. 6th IAS Conference on HIV pathogenesis, treatment and prevention 17-20 July 2011, Rome.
9. Lambert-Niclot S, Flandre P, Valantin MA, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis. 2011;204:1211-6.
10. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24:223-30.
11. Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother. 2011;66:1878-85.
12. Arribas J, Hill A, Van Delft Y, et al. Interleukin-6 and C-reactive protein levels after 144 weeks of DRV/r monotherapy versus DRV/r + 2NRTIs in the MONET trial, for patients with HIV RNA <50 copies/mL at baseline [abstract PS 10/2]. European AIDS Clinical Society Conference, Belgrade, Serbia, October 2011.
13. Pulido F, Arribas JR, Hill A, Van Delft Y, et al. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther. 2011;16:59-65.
14. Winston A, Fätkenheuer G, Arribas J, et al. Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. HIV Clin Trials. 2010;11:163-9.
15. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
16. Winston A, Arribas J, Hill A, et al. Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir with or without nucleoside analogues [abstract P049]. Adverse Events/Lipodystrophy Workshop, Rome, Italy, June 2011.
17. Rodger AJ, Fox Z, Lundgren JD, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200:973-83.
18. Kuller LH, Tracy R, Belloso W, INSIGHT SMART Study Group, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
19. Ueyama M, Nakagawa M, Sakamoto N, Ochanomizu-Liver Conference Study Group, et al. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin. Antivir Ther. 2011;16:1081-91.
20. Oliveira CP, Kappel CR, Siqueira ER, et al. Effects of Hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2011. [Epub ahead of print].
21. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24:2365-74.
22. Valantin MA, Lambert-Niclot S, Flandre P, et al.; on behalf of the MONOI ANRS 136 Study Group. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2011. Dec 7 [Epub ahead of print].
23. Meynard JL, Bouteloup V, Landman R, KALESOLO Study Group, et al. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother. 2010;65:2436-44.
24. Duran S, Peytavin G, Carrieri P, Antiprotease Cohort (APROCO) study group, et al. The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. AIDS. 2003;17:1096-9. (Pubitemid 36549728)
25. McKinnon JE, Delgado R, Pulido F, et al. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antivir Ther. 2011;16:725-32.
26. Pulido F, Arribas JR, Delgado R, OK04 Study Group, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1-9.
27. Cahn P, Montaner J, Junod P, et al. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. PLoS One. 2011;6:e23726.
28. Arribas JR, Delgado R, Arranz A, Muñoz R, OK04 Study Group, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51:147-52.
29. Nunes EP, Santini de Oliveira M, Merçon M, et al. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMostudy). HIV Clin Trials. 2009;10:368-74.
30. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS. 2008;22:385-93.
31. Ghosn J, Flandre P, Cohen-Codar I, MONARK Study Group, et al. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010;11:137-42.
32. Delaugerre C, Flandre P, Chaix ML, MONARK Study Group, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother. 2009;53:2934-9.
33. Ghosn J, Delaugerre C, Flandre P, et al. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One. 2011;6:e24798.
34. Saumoy M, Tiraboschi J, Gutierrez M, et al. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV Med. 2011;12:438-41.
35. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198:234-40. (Pubitemid 352019289)
36. Valantin MA, Flandre P, Kolta S, et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV/r monotherapy vs 2 NRTI + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks [Abstract 721]. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, 16-19 February 2010.
37. Guaraldi G, Zona S, Cossarizza A, et al. Impact of Switching to Darunavir/ritonavir monotherapy vs. triple-therapy on Body Fat Redistribution and Bone Mass in Virologically Suppressed HIV-Infected Adults [PE7.5/4.] The MONARCH randomized controlled trial. 13th European AIDS Conference EACS, Belgrade, Serbia, October 2011.
38. Knysz B, Briot K, Roux C, Delfraissy JF, et al. Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. CurrHIV Res. 2011;9:31-9.
39. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-801.
40. Gutiérrez F, Masiá M. The role of HIV and antiretroviral therapy in bone disease. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev. 2011;13:109-18.
41. Bonjoch A, Figueras M, Estany C, Osteoporosis Study Group, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24(18):2827-33.
42. Briot K, Kolta S, Flandre P, et al. Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies. Bone. 2011;48:1133-9.
43. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune DeficSyndr. 2009;51(5):554-61.
44. Mueller NJ, Fux CA, Ledergerber B, Swiss HIV Cohort Study, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24:1127-34.
45. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923-8.
46. Fux CA, Baumann S, Furrer H, et al. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? AIDS. 2011;25:876-8.
47. Fox J, Peters B, Prakash M, et al. Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retrovir. 2011;27:29-34.